TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02512744

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decannulation protocol.
Description: Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow conditioned oxygen therapy
Description: High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
Study: NCT04047758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib + Letrozole
Description: (1) Palbociclib (trade name: Ibrance®; Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany; imported drug license No. H20180040): 125 mg/capsule, 1 capsule by mouth once a day, for 21 successive days, followed by 7 days off treatment \[3 weeks on (days 1-21) and 1 week off (days 22-28)\], repeated every 28 days. (2) Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole
Description: Letrozole (trade name: Femara®; Novartis Pharma Schweiz AG, Switzerland; imported drug license No. H20140149): 2.5 mg/table, 1 table by mouth once a day, continuously for a 28-day cycle.
Study: NCT00965783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restriction
Description: Time in bed for each subject is restricted by two hours per night for 4 nights

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension
Description: Bedtime is extended by 2 hours per night for 4 nights
Study: NCT06360575

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study: NCT00592553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ataluren
Description: Ataluren will be administered as per the dose and schedule specified in the respective arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to ataluren will be administered as the schedule specified in the respective arm.
Study: NCT01773096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Description: Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
Description: Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax
Description: Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
Study: NCT01853436

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strattice™ Reconstructive Tissue Matrix
Description: Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
Study: NCT01946074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-181
Description: ABBV-181 will be administered by intravenous infusion.
Study: NCT03999671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational
Description: Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational
Description: Traditional method of nursing care with what is done every day, with the method through the nursing process using nursing language as a nursing diagnosis, classification of nursing interventions, and nursing outcomes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maneuver control
Description: Verify that the control and intervention group developed the assigned activities in each case.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maneuver control
Description: Verify that the control and intervention group developed the assigned activities in each case.
Study: NCT02628171

Intervention type: OTHER
Group type: OTHER
Intervention: Base Diet
Description: Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Base Diet with Cashew Nuts
Description: Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
Study: NCT03230786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily injection of KBP/placebo for 12 weeks as add-on to metformin
Description: Daily subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily injection of KBP/placebo for 12 weeks as add-on to metformin
Description: Daily subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily injection of KBP/placebo for 12 weeks as add-on to metformin
Description: Daily subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Daily injection of KBP/placebo for 12 weeks as add-on to metformin
Description: Daily subcutaneous injection
Study: NCT03524534

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Call
Description: A phone call will take place within 7 days of discharge by a Kaiser Permanente Heart Failure Care Manager from the Kaiser Permanente Heart Failure Chronic Care Management Program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Primary Care Clinical Follow-Up Visit
Description: This will be a standard in-person clinic visit with the subject's primary care physician within 7 days of discharge, with no structured heart failure protocol.
Study: NCT00598377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracosactin
Description: 1 microgram tetracosactin, intravenous injection, once for the test

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracosactin
Description: 1 microgram tetracosactin, intravenous injection, once for the test
Study: NCT05816902

Intervention type: OTHER
Intervention: The location of the patient's treatment
Description: The location of the patient's treatment

Intervention type: OTHER
Intervention: The location of the patient's treatment
Description: The location of the patient's treatment
Study: NCT03173105

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS
Description: TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic proprioceptive exercises
Description: The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: static proprioceptive exercises
Description: The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
Study: NCT04238429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 10% high cleaning silica base, 0.5% sodium phytate and 0.5% sodium pyrophosphate
Description: Use the toothpaste to brush teeth twice a day for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control toothpaste
Description: Use the toothpaste to brush teeth twice a day for 8 weeks
Study: NCT01087255

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electronic Pillbox Monitoring System
Description: Daily exposure for six months
Study: NCT02176538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 0405
Description: Product 0405 will be administered topically twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Product 0405
Description: Placebo for Product 0405 will be administered topically twice daily for 28 days.
Study: NCT03431922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular denervation
Description: multi-electrode catheter-based endovascular denervation
Study: NCT05862194

Intervention type: DRUG
Intervention: Lazertinib
Description: Patients who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period

Intervention type: DRUG
Intervention: Platinum-based Chemotherapy
Description: Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
Study: NCT02103270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Protein 4,000mg
Description: Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oat Flour
Description: Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oat Flour
Description: Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oat Flour
Description: Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peanut Protein 300 mg
Description: Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study).
Study: NCT02151929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold
Description: stenting of an acute thrombotic lesion in patient within STEMI
Study: NCT02327065

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA (EchoTip Ultra)
Description: FNA,Fine needle aspiration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNB (EchoTip ProCore)
Description: FNB,Fine needle biopsy
Study: NCT03642457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 cc 0.5%
Study: NCT02151929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stent
Description: stenting of an acute thrombotic lesion in patient within STEMI
Study: NCT03642457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine liposome
Description: 133mg liposomal bupivacaine
Study: NCT00647543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
Study: NCT03244423

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline at induction
Description: 0.5 ml/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline at induction
Description: 0.5 ml/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: 1ml/kg/hr. during surgery for six hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline infusion
Description: 1ml/kg/hr. during surgery for six hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tranexamic acid
Description: 50 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infusion tranexamic acid
Description: 1mg/kg/hr infusionfor 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical tranexamic acid
Description: 50 mg/kg added to the normal saline 2 ml/kg into the pericardial cavity before sternal closure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: topical normal saline
Description: 2 ml/kg into the pericardial cavity before sternal closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical normal saline
Description: 2 ml/kg into the pericardial cavity before sternal closure
Study: NCT02021253

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Lactibiane TOLERANCE vs Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04154150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Description: Single subanesthetic infusion of ketamine (0.5mg/kg)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous ketamine
Description: Single subanesthetic infusion of ketamine (0.5mg/kg)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: 8 sessions of computer-based cognitive training
Study: NCT03642457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine liposome
Description: 133mg liposomal bupivacaine
Study: NCT00647543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
Study: NCT01301677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone liquid formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2PX+
Description: strontium chloride hexahydrate in a penetration enhancing vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2PX-
Description: strontium chloride hexahydrate without a penetration enhancing vehicle
Study: NCT03431454

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trained to do the pencil push-ups procedure
Description: 15 minutes per day, five days a week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: using a major amblyoscope twice weekly with additional home orthoptic therapy
Description: 60 minutes of orthoptic therapy using a major amblyoscope twice weekly with additional home orthoptic therapy was prescribed.
Study: NCT03552731

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.
Study: NCT04154150

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: 8 sessions of computer-based sham training
Study: NCT03431454

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: using three diopter over-minus lenses and a base out prism
Description: For the augmented office-based vision orthoptic therapy (AOBVOT) group, orthoptic exercises using three diopter over-minus lenses and a base out prism, in addition to major amblyoscope and additional home reinforcement was prescribed in the same period of time.
Study: NCT01674790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of motion exercise
Description: One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of motion exercise
Description: One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Range of motion exercise
Description: One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unstructured mental activity
Description: One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
Study: NCT00530881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PHX1149

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PHX1149
Study: NCT04144660

Intervention type: DEVICE
Intervention: Extracorporeal Membrane Oxygenation
Description: Use of ECMO for circulatory / hemodynamic support of peripartum of pregnant patients who developed cardiogenic shock.
Study: NCT02570074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Broad spectrum antibiotic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosfomycin
Description: Broad spectrum antibiotic
Study: NCT01853436

Intervention type: DEVICE
Group type: OTHER
Intervention: Strattice™ Reconstructive Tissue Matrix
Description: Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
Study: NCT02469792

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRC isolation
Description: ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
Study: NCT04073056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine Hcl 0.25% Inj

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine Hcl 0.25% Inj
Study: NCT02724241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one time exposure to e-cig with nicotine
Description: one time exposure to e-cigarette vapor with nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One time exposure to e-cigarette without nicotine
Description: One time exposure to e-cig without nicotine

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: one time exposure to empty e-cigarette
Description: one time exposure to empty e-cigarette (sham control)
Study: NCT03637400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMP-SMX
Description: TMP-SMX will be administered over a period of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXY
Description: DOXY will be administered over a period of 7 days.